We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03697109
Recruitment Status : Recruiting
First Posted : October 5, 2018
Last Update Posted : July 20, 2022
Information provided by (Responsible Party):
Corcept Therapeutics

Brief Summary:
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes mellitus/impaired glucose tolerance and/or uncontrolled hypertension

Condition or disease Intervention/treatment Phase
Cushing Syndrome Drug: Relacorilant Other: Placebo Phase 3

Detailed Description:
This Phase 3 study involves two phases, an open-label (OL) phase and a randomized-withdrawal (RW) phase. Patients will dose-escalate in 100 mg increments to a target dose of 400 mg orally once daily during the open-label phase. Patients will remain on open-label treatment until week 22 at which time they will be evaluated for the randomized-withdrawal phase based on pre-defined hyperglycemia and hypertension response criteria. Eligible patients will then be randomized to receive either relacorilant or placebo at a 1:1 ratio for 12 weeks. Patients who do not meet the criteria for randomization will end treatment and may be eligible to roll over into an extension safety study. Patients who complete the randomized-withdrawal phase of the study may also be eligible to roll over into an extension study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant
Actual Study Start Date : October 16, 2018
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : December 2022

Arm Intervention/treatment
Experimental: Relacorilant (open-label phase)
The dose of relacorilant will be increased sequentially from 100 mg orally once daily to a target dose of 400 mg once daily.
Drug: Relacorilant
Relacorilant is supplied as 100 mg capsules for oral dosing.
Other Name: CORT125134

Experimental: Relacorilant (randomized-withdrawal phase)
Patients who meet any of the response criteria will advance to the randomized-withdrawal phase of the study and receive the same highest dose as in the open-label phase.
Drug: Relacorilant
Relacorilant is supplied as 100 mg capsules for oral dosing.
Other Name: CORT125134

Placebo Comparator: Placebo (randomized-withdrawal phase)
Placebo matched to study drug
Other: Placebo
Placebo matched to study drug

Primary Outcome Measures :
  1. In patients with diabetes mellitus/impaired glucose tolerance (DM/IGT), the mean change in area under the curve for glucose from Week OL22 to Week RW12 as compared between relacorilant and placebo [ Time Frame: Week Open label 22 (OL22) to Week Randomized withdraw 12 (RW12) ]
  2. In patients with hypertension, the proportion of patients with a loss of response with respect to hypertension from visit OL22 to RW12 [ Time Frame: Week OL22 to Week RW12 ]
    Based on 24hour ABPM defined as 1) an increase in systolic and/or diastolic blood pressure of at least 5 mmHg or 2) any increase or modification in antihypertensive medication from Week OL22 to Week RW12/Early Termination as compared between relacorilant and placebo

  3. In all patients, assessment of safety based on treatment-emergent adverse events (TEAEs) as graded by CTCAE v5.0. [ Time Frame: Screening through Post Treatment Follow-up (up to 48 weeks) ]

Secondary Outcome Measures :
  1. In patients with DM (HbA1c at Baseline >6.5%), the mean change from Visit OL22 to RW12 in HbA1c as compared between relacorilant and placebo. [ Time Frame: Open Label week 22 (OL22) to Randomized Withdraw week 12 (RW12) ]
  2. In patients with IGT at Baseline, the mean change from Visit OL22 to RW12 in the 2 hour glucose value of the oGTT [ Time Frame: Week OL22 to week RW12 ]
  3. In patients with hypertension the mean change in SBP or DBP as compared between relacorilant and placebo [ Time Frame: Week OL22 to week RW12 ]
  4. The mean change in body weight, body fat measured with DXA scan and Cushing Quality-of-Life (QoL) score as compared between relacorilant and placebo [ Time Frame: Week OL22 to week RW12 ]
    The Cushing Quality of Life (QoL) patient questionnaire, which evaluates the health-related QoL in patients with Cushing syndrome (Webb et al. 2008), will be administered to all patients. It comprises 12 questions, each with 5 possible answers. The total score ranges from 12-60. The Cushing QoL instrument addresses known problem areas associated with Cushing syndrome including trouble sleeping, wound healing/bruising, irritability/mood swings/anger, self-confidence, physical changes, ability to participate in activities, interactions with friends and family, memory issues, and future health concerns. Lower values reflect lower quality of life.

  5. For patients in either subgroup (DM/IGT or hypertension) the proportion of patients with any increase or modification in diabetes or antihypertensive medication as compared between relacorilant and placebo [ Time Frame: Week OL22 to week RW12 ]
  6. Proportion of patients who worsened, as assessed by the Global Clinical Response, from Week OL22 to Week RW12/ET as compared between relacorilant and placebo [ Time Frame: Week OL22 to Week RW12 ]

    Global Clinical Response will be scored in 7 categories: glucose, blood pressure, body composition, clinical appearance, strength, psychiatric health/ cognitive function, Cushing QoL score.

    An independent Data Review Board (DRB) will review the 7 categories of clinical parameters above to evaluate whether a patient's signs and symptoms of Cushing syndrome have changed and will rate each patient's overall response based on the totality of signs and symptoms as +1 (improved), 0 (unchanged), or -1 (worsened) at every visit after Baseline. Each patient's final score will be the median of the 3 ratings

  7. Mean change in QoL, body fat composition as determined by DXA, Beck Depression inventory-II (BDI-II) and body weight from Baseline to visit OL22 or end of treatment (ET) [ Time Frame: Baseline to week OL22 or End of Treatment (ET) ]
  8. In patients with IGT, the mean change in 2-hour oGTT glucose from Baseline to Visit OL22/ET [ Time Frame: Baseline to week OL22 or ET ]
  9. In patients with DM (HbA1c ≥6.5% at Baseline), the mean change in HbA1c from Baseline to Visit OL22/ET [ Time Frame: Baseline to week OL22 or ET ]
  10. In patients with uncontrolled hypertension the mean change in SBP or DBP from Baseline to visit OL22/ET [ Time Frame: Baseline to week OL22 or ET ]
    Blood pressure will be measured by 24 hour ABPM readings

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has a confirmed diagnosis of endogenous Cushing syndrome
  • Meets at least one of the following criteria:
  • Has Type 2 diabetes mellitus
  • Has impaired glucose tolerance
  • Has hypertension

Exclusion Criteria:

  • Has non-endogenous source of hypercortisolemia
  • Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
  • Has poorly controlled hypertension
  • Has poorly controlled diabetes mellitus
  • Has severe renal insufficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03697109

Layout table for location contacts
Contact: Clinical Trial Lead 650-327-3270 CorceptStudy455@corcept.com

Hide Hide 69 study locations
Layout table for location information
United States, Arizona
Site 21 Recruiting
Phoenix, Arizona, United States, 85013
United States, California
Site 36 Recruiting
Los Angeles, California, United States, 90095
Site 42 Recruiting
Santa Monica, California, United States, 90404
Site 68 Recruiting
Torrance, California, United States, 90502
United States, Colorado
Site 9 Recruiting
Aurora, Colorado, United States, 80045
United States, District of Columbia
Site 32 Recruiting
Washington, District of Columbia, United States, 20010
United States, Florida
Site 52 Withdrawn
Gainesville, Florida, United States, 32610
Site 10 Recruiting
Miami, Florida, United States, 33136
United States, Georgia
Site 14 Recruiting
Atlanta, Georgia, United States, 30318
United States, Illinois
Site 41 Withdrawn
Chicago, Illinois, United States, 60611
United States, Indiana
Site 7 Recruiting
Indianapolis, Indiana, United States, 46202
United States, Louisiana
Site 2 Recruiting
Metairie, Louisiana, United States, 70006
United States, Maryland
Site 45 Recruiting
Baltimore, Maryland, United States, 21205
United States, Massachusetts
Site 46 Recruiting
Boston, Massachusetts, United States, 02115
United States, Michigan
Site 20 Recruiting
Ann Arbor, Michigan, United States, 48109
United States, Mississippi
Site 4 Recruiting
Jackson, Mississippi, United States, 39202
United States, Missouri
Site 13 Recruiting
Saint Louis, Missouri, United States, 63110
United States, Nebraska
Site 53 Recruiting
Omaha, Nebraska, United States, 68198
United States, New York
Site 8 Recruiting
Albany, New York, United States, 12203
Site 6 Withdrawn
Jamaica, New York, United States, 11432
Site 57 Recruiting
New York, New York, United States, 10021
Site 35 Withdrawn
New York, New York, United States, 10029
Site 39 Recruiting
New York, New York, United States, 10065
United States, North Carolina
Site 1 Withdrawn
Wilmington, North Carolina, United States, 28401
United States, Ohio
Site 44 Withdrawn
Cleveland, Ohio, United States, 44195
Site 17 Recruiting
Columbus, Ohio, United States, 43210
United States, Oklahoma
Site 11 Recruiting
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Site 62 Recruiting
Philadelphia, Pennsylvania, United States, 19107
Site 19 Withdrawn
Pittsburgh, Pennsylvania, United States, 15212
United States, South Carolina
Site 5 Withdrawn
Summerville, South Carolina, United States, 29485
United States, Texas
Site 51 Recruiting
Dallas, Texas, United States, 75390
Site 3 Recruiting
El Paso, Texas, United States, 79935
Site 18 Withdrawn
Houston, Texas, United States, 77030
Site 65 Recruiting
Houston, Texas, United States, 77079
Site 56 Withdrawn
Shavano Park, Texas, United States, 78231
United States, Washington
Site 31 Recruiting
Everett, Washington, United States, 98201
Site 60 Recruiting
Graz, Austria, 8036
Site 47 Recruiting
Vienna, Austria, 1090
Site 27 Recruiting
Sofia, Bulgaria, 1431
Canada, British Columbia
Site 55 Recruiting
Vancouver, British Columbia, Canada, V6Z 1Y6
Site 58 Recruiting
Montréal, Canada, H2X 0A9
Site 50 Recruiting
Leipzig, Germany, 04103
Site 54 Recruiting
München, Germany, 80336
Site 49 Recruiting
Würzburg, Germany, 97080
Site 30 Recruiting
Jerusalem, Israel, 911120
Site 29 Recruiting
Kfar Saba, Israel, 4428164
Site 28 Recruiting
Petach Tikva, Israel, 4941480
Site 70 Recruiting
Tel Aviv, Israel
Site 43 Recruiting
Ancona, Italy, 60030
Site 15 Recruiting
Messina, Italy, 98125
Site 26 Recruiting
Milano, Italy, 20149
Site 12 Recruiting
Napoli, Italy, 80131
Site 38 Recruiting
Orbassano, Italy, 10043
Site 67 Recruiting
Padova, Italy, 35128
Site 40 Recruiting
Roma, Italy, 00161
Site 16 Recruiting
Roma, Italy, 00189
Site 48 Recruiting
Torino, Italy, 10126
Site 34 Recruiting
Rotterdam, Netherlands, 3015 AA
Site 37 Recruiting
Chrzanów, Poland, 32-500
Site 59 Recruiting
Kraków, Poland, 31- 501
Site 33 Recruiting
Lublin, Poland, 20-412
Site 66 Recruiting
Bucharest, Romania, 010825
Site 63 Recruiting
Bucharest, Romania, 011863
Site 64 Recruiting
Bucharest, Romania, 011863
Site 61 Withdrawn
Barcelona, Spain, 08041
Site 25 Recruiting
Girona, Spain, 17007
Site 24 Recruiting
Madrid, Spain, 28007
Site 22 Recruiting
Málaga, Spain, 29006
Site 23 Recruiting
Sevilla, Spain, 41013
Sponsors and Collaborators
Corcept Therapeutics
Layout table for investigator information
Study Director: Andreas Moraitis, MD Corcept Therapeutics
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Corcept Therapeutics
ClinicalTrials.gov Identifier: NCT03697109    
Other Study ID Numbers: CORT125134-455
First Posted: October 5, 2018    Key Record Dates
Last Update Posted: July 20, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Corcept Therapeutics:
Cushing syndrome
Cushing disease
Type 2 Diabetes
Impaired Glucose Intolerance
Adrenocorticotropic hormone
Primary Pigmented Nodular Adrenal Disease
Moon Facies
Dorsocervical Fat Pad
Adrenal Adenoma
Adrenal Autonomy
Additional relevant MeSH terms:
Layout table for MeSH terms
Cushing Syndrome
Pathologic Processes
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases